GoodRx (GDRX) Projected to Post Quarterly Earnings on Wednesday

GoodRx (NASDAQ:GDRX) is anticipated to announce its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $185.1190 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09. The business had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.09 earnings per share. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Stock Performance

Shares of GoodRx stock opened at $2.55 on Monday. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.78. The firm has a market cap of $873.55 million, a price-to-earnings ratio of 28.34, a price-to-earnings-growth ratio of 1.76 and a beta of 1.54. The business has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $2.61. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GDRX shares. Mizuho cut their price objective on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. Citigroup cut their target price on GoodRx from $4.50 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Bank of America reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Finally, Wells Fargo & Company cut their target price on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new position in GoodRx in the third quarter valued at about $33,000. MML Investors Services LLC bought a new stake in shares of GoodRx during the 4th quarter worth about $36,000. DRW Securities LLC bought a new stake in shares of GoodRx during the 4th quarter worth about $40,000. Boothbay Fund Management LLC bought a new stake in shares of GoodRx during the 3rd quarter worth about $43,000. Finally, EP Wealth Advisors LLC bought a new stake in shares of GoodRx during the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.